Fennec Pharmaceuticals Inc. (T:FRX)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

May 07, 2024 06:15 pm ET

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on...

Mar 21, 2024 06:00 am ET

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2023 and provided a business update. “It was an exciting year for Fennec given the...

Mar 19, 2024 06:01 am ET

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S....

Mar 17, 2024 09:00 pm ET

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will...

Feb 29, 2024 07:04 am ET

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues. The information in this press release is based upon...

Feb 01, 2024 05:55 am ET

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a public reminder to healthcare providers that PEDMARK (sodium...

Dec 05, 2023 05:55 am ET

Fennec Announces Incremental $5 Million Investment from Petrichor

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company focused on improving the lives of children with cancer, today announced the third closing of $5 million senior secured promissory notes under...

Nov 09, 2023 04:50 pm ET

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor...

Nov 06, 2023 05:59 am ET

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2023 and provided a business update. “We continued to see...

Oct 30, 2023 06:45 am ET

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2023 financial results before the opening of the U.S. financial markets on...

Sep 07, 2023 05:59 am ET

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 03, 2023 05:59 am ET

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2023 and provided a business update. “During the second quarter,...

Jul 31, 2023 05:30 am ET

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2023 financial results before the opening of the U.S. financial markets on...

Jun 12, 2023 05:00 pm ET

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 24, 2023 (the “Circular”) for the Annual General Meeting of Shareholders were elected as...

Jun 06, 2023 05:44 am ET

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced Pedmarqsi™– known as PEDMARK® in the U.S. – was granted marketing authorization by the European Commission. Pedmarqsi is the...

May 11, 2023 06:01 am ET

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal quarter ended March 31, 2023 and provided a business update. “During the first quarter, we continued to...

May 08, 2023 06:15 am ET

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial markets on...

Mar 31, 2023 08:03 am ET

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive...

Mar 30, 2023 05:55 am ET

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2022 and provided a business update. “It was an outstanding year for Fennec as...

Jan 31, 2023 06:00 am ET

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity to PEDMARK® (sodium thiosulfate...

Jan 25, 2023 07:19 am ET

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the National Comprehensive Cancer Network® (NCCN) has updated its clinical practice guidelines for Adolescent and Young...

Nov 11, 2022 07:10 am ET

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company focused on the development of PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric...

Oct 17, 2022 08:00 am ET

Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the U.S. commercial launch and availability of PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity...

Sep 26, 2022 07:35 am ET

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that it has completed the second closing of $20 million of senior secured promissory notes under our previously announced investment agreement...

Sep 21, 2022 07:00 am ET

Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity...

Aug 22, 2022 07:04 am ET

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed the first closing of US$5 million of senior secured promissory notes under our previously announced investment agreement with...

Aug 12, 2022 06:59 am ET

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric...

Aug 01, 2022 07:30 am ET

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced up to a US$45 million investment from Petrichor Healthcare Capital Management ("Petrichor"). Under the terms of the investment agreement:...

Jun 14, 2022 06:00 pm ET

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 20, 2022 (the “Circular”) for the Annual General Meeting of Shareholders were elected as...

May 23, 2022 07:29 am ET

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

May 12, 2022 06:00 am ET

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

Apr 27, 2022 06:00 am ET

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM (a...

Mar 25, 2022 07:00 am ET

Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Mar 24, 2022 06:00 am ET

Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark™

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™ (a unique formulation of sodium...

Feb 28, 2022 06:00 am ET

Fennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric...

Jan 31, 2022 06:00 am ET

Fennec Pharmaceuticals Announces Management Change

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Nov 30, 2021 06:00 am ET

Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, N

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on November 29, 2021 from the U.S. Food and Drug Administration (FDA), after the PDUFA target action date of November...

Nov 29, 2021 06:00 am ET

Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Lo

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it expects to receive a Complete Response Letter (CRL) after the PDUFA target action date of November 27, 2021 from the U.S. Food and Drug Administration (FDA)...

Nov 10, 2021 06:00 am ET

Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Sep 09, 2021 06:00 am ET

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Aug 10, 2021 06:00 am ET

Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Jun 29, 2021 05:30 pm ET

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company...

Jun 24, 2021 06:00 am ET

Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients...

Jun 22, 2021 06:00 am ET

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of its New Drug Application (NDA) for PEDMARK™ (a...

May 28, 2021 06:00 am ET

Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™ (a unique formulation of sodium...

May 13, 2021 06:00 am ET

Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Mar 30, 2021 06:00 am ET

Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

Nov 16, 2020 07:01 am ET

Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Sep 21, 2020 06:00 am ET

Fennec Announces Issuance of U.S. Patent for PEDMARK™

Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric...

Aug 12, 2020 06:00 am ET

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that Rosty Raykov, Chief Executive Officer of Fennec will present at the following upcoming investor conferences. The following presentations will be webcast live and...

Aug 11, 2020 06:04 am ET

Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, N

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on August 10, 2020 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for...

Aug 05, 2020 06:00 am ET

Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Jun 26, 2020 06:00 am ET

Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

Jun 22, 2020 06:04 pm ET

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 7, 2020 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected...

May 14, 2020 06:00 am ET

Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

May 08, 2020 06:00 am ET

Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in...

May 05, 2020 06:00 am ET

Fennec Announces Closing of Public Offering

Apr 30, 2020 09:16 am ET

Fennec Announces Pricing of Public Offering

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in...

Apr 29, 2020 04:01 pm ET

Fennec Announces Proposed Public Offering of Common Shares

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in...

Apr 13, 2020 07:08 am ET

Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™

Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review for the company’s New Drug Application...

Mar 05, 2020 07:00 am ET

Fennec Announces Issuance of U.S. Patent for Use of PEDMARK™

Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric...

Feb 28, 2020 06:00 am ET

Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate

Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the company’s Marketing Authorization Application (MAA) for its investigational drug, sodium thiosulfate (unique formulation) for...

Feb 14, 2020 06:00 am ET

Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results

Feb 11, 2020 06:00 am ET

Fennec Pharmaceuticals Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for PEDMARK™ and Also Submits Marketing Authorization Application (MAA) to Europe

Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™ (a unique...

Nov 12, 2019 06:00 am ET

Fennec Provides Business Update and Announces Third Quarter 2019 Financial Results

Oct 02, 2019 06:00 am ET

Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

Sep 24, 2019 06:00 am ET

Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors

Sep 09, 2019 06:00 am ET

Fennec Appoints Shubh Goel as Chief Commercial Officer

Aug 09, 2019 06:00 am ET

Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results

Jun 19, 2019 06:00 am ET

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2019 (the “Circular”) for the Annual General and Special Meeting of Shareholders were...

May 09, 2019 06:00 am ET

Fennec Provides Business Update and Announces First Quarter 2019 Financial Results

Mar 13, 2019 06:19 am ET

Fennec Provides Business Update and Announces Fiscal Year 2018 Financial Results

Feb 04, 2019 06:00 am ET

Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS) to be administered by infusion) for the prevention of ototoxicity...

Dec 20, 2018 06:00 am ET

Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, following a pre-submission meeting with the oncology division of the U.S. Food and Drug Administration (FDA), has initiated a rolling New Drug Application...

Nov 16, 2018 06:00 am ET

Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting

Nov 13, 2018 06:00 am ET

Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric...

Sep 26, 2018 06:00 am ET

Fennec to Present at Cantor Fitzgerald Global Healthcare Conference on October 1, 2018 in New York City

Sep 05, 2018 07:00 am ET

September 13 Meeting Will Explore Chemo-Induced Hearing Loss in Pediatrics

Young adult survivors of childhood cancer and parents of children with cancer are invited to participate via webcast in a workshop on Chemotherapy-Induced Hearing Loss in Pediatrics, taking place in the DC metro area on September 13, 2018. This...

Aug 13, 2018 06:00 am ET

Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results

Aug 07, 2018 06:00 am ET

Fennec Pharmaceuticals Receives Positive Opinion on the Pediatric Investigation Plan From European Medicines Agency for PEDMARK(TM) and Confirmation of Eligibility for a Pediatric Use Marketing Author

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s pediatric investigation plan (PIP) for...

Jun 21, 2018 06:00 am ET

Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)), announced today a publication in the June 21, 2018 issue of the New...

Jun 11, 2018 06:00 am ET

Fennec Pharmaceuticals Set to Join Russell 3000 Index

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric...

Jun 08, 2018 07:00 am ET

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 30, 2018 (the “Circular”) for the Annual General and Special Meeting of Shareholders were...

May 14, 2018 06:00 am ET

Fennec Provides Business Update and Announces First Quarter 2018 Financial Results

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric...

Mar 27, 2018 06:30 am ET

Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™

RESEARCH TRIANGLE PARK, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted PEDMARK™ (a unique formulation of sodium thiosulfate)...

Mar 26, 2018 06:30 am ET

Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results

RESEARCH TRIANGLE PARK, N.C., March 26, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity...

Mar 21, 2018 06:30 am ET

Fennec Pharmaceuticals Receives Fast Track Designation by FDA for PEDMARK

RESEARCH TRIANGLE PARK, N.C., March 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted PEDMARK (a unique formulation of sodium thiosulfate)...

Dec 12, 2017 04:01 pm ET

Fennec Announces Closing of Public Offering

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity from cisplatin...

Dec 08, 2017 08:54 am ET

Fennec Announces Pricing of Public Offering

RESEARCH TRIANGLE PARK, N.C., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity from...

Dec 07, 2017 04:01 pm ET

Fennec Announces Proposed Public Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity from cisplatin...

Nov 13, 2017 06:00 am ET

Fennec Provides Business Update And Reports Third Quarter 2017 Results

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in...

Sep 13, 2017 01:35 pm ET

IIROC Trade Resumption - FRX

TORONTO, Sept. 13, 2017 /CNW/ - Trading resumes in:

Sep 13, 2017 10:29 am ET

IIROC Trading Halt - FRX

TORONTO, Sept. 13, 2017 /CNW/ - The following issues have been halted by IIROC:

Sep 11, 2017 08:29 am ET

Fennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market

RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (TSX:FRX), (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that its shares of common stock were approved for listing on the Nasdaq Capital Market ("Nasdaq"). Trading on the Nasdaq under the symbol "FENC" is expected to commence on September 13, 2017....

Aug 11, 2017 06:00 am ET

Fennec Provides Corporate Update and Announces Second Quarter 2017 Results

Fennec Pharmaceuticals Inc. (TSX: FRX) (OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the second quarter ended June 30, 2017.

Aug 11, 2017 05:58 am ET

Fennec Provides Corporate Update and Announces Second Quarter 2017 Results

Jun 28, 2017 12:59 pm ET

Fennec Announces Results of Annual Meeting

Jun 28, 2017 12:59 pm ET

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated May 19, 2017 (the "Circular") for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 27, 2017. Detailed results of the vote for the election of directors are set out below:

Jun 08, 2017 05:00 pm ET

Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed a non-brokered private placement (the "Offering") of 1,900,000 common shares for gross proceeds of US$7,600,000. The common shares of the Company (the "Shares") were issued at a price of US$4.00 per Share. The current number of outstanding Shares prior to

Jun 08, 2017 04:58 pm ET

Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor

May 30, 2017 06:00 am ET

Fennec Announces Launch of European Named Patient Programme for Sodium Thiosulfate for Pediatric Patients With Standard Risk Hepatoblastoma

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced the launch of a Named Patient Programme (NPP) in Europe for STS. Fennec's NPP is intended to make STS available to patients before commercial availability in certain countries. Where mechanisms exist and in accordance with local regulations, Fennec will make STS available for pediatric patients with Standard Risk Hepatoblastoma.

May 30, 2017 05:58 am ET

Fennec Announces Launch of European Named Patient Programme for Sodium Thiosulfate for Pediatric Patients With Standard Risk Hepatoblastoma

May 12, 2017 06:00 am ET

Fennec Provides Corporate Update and Announces First Quarter 2017 Results

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the first quarter ended March 31, 2017.

May 12, 2017 05:58 am ET

Fennec Provides Corporate Update and Announces First Quarter 2017 Results

Apr 27, 2017 06:00 am ET

Fennec to Present at Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City

Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the PIONEERS 2017 Joseph Gunnar Conference on Tuesday, May 2 at 2:00 PM ET in the South Salon II at the Mandarin Oriental Hotel in New York City. Management will also be available to meet with investors during the conference.

Apr 27, 2017 05:58 am ET

Fennec to Present at Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City

Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the PIONEERS 2017 Joseph Gunnar Conference on Tuesday, May 2 at 2:00 PM ET in the South Salon II at the Mandarin Oriental...

Mar 30, 2017 06:00 am ET

Fennec Provides Corporate Update and Announces Fiscal Year Ended December 31, 2016 Financial Results

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2016.

Mar 30, 2017 05:58 am ET

Fennec Provides Corporate Update and Announces Fiscal Year Ended December 31, 2016 Financial Results

Feb 09, 2017 05:00 pm ET

Fennec to Present at 19th Annual BIO CEO & Investor Conference

Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the 19th BIO CEO & Investor Conference on Monday, February 13, 2017 at 1:30 PM ET at the Waldorf Astoria Hotel in New York City.

Feb 09, 2017 04:58 pm ET

Fennec to Present at 19th Annual BIO CEO & Investor Conference

Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the 19th BIO CEO & Investor Conference on Monday, February 13, 2017 at 1:30 PM ET at the Waldorf Astoria Hotel in New York...

Dec 01, 2016 06:00 am ET

Fennec Announces the Lancet Oncology Publication of Children's Oncology Group Study of Sodium Thiosulfate

Fennec Pharmaceuticals Inc. (TSX: FRX) (OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced The Lancet Oncology published the results from the Children's Oncology Group, "Effects of Sodium Thiosulfate versus Observation on Development of Cisplatin-Induced Hearing Loss and Survival in Children with Cancer: Results from the Children's Oncology Group ACCL0431 Randomised Cohort Trial".

Dec 01, 2016 05:58 am ET

Fennec Announces the Lancet Oncology Publication of Children's Oncology Group Study of Sodium Thiosulfate

Nov 15, 2016 05:00 pm ET

Fennec Announces Repricing of Warrants

Fennec Pharmaceuticals Inc. (the "Company" or "Fennec") (TSX: FRX)(OTCQB: FENCF) announced today that its board of directors has approved an amendment to the exercise price of the outstanding 366,133 common share purchase warrants originally issued on December 3, 2014 from USD$3.60 to USD$2.50 (the "Amendment"). No other changes will be made to the terms of the Warrants, and the Warrants expire on December 3, 2016. The volume-weighted average trading price of the Company's common shares on the Toronto Stock Exchange (the "TSX") for the five-trading-day

Nov 15, 2016 04:58 pm ET

Fennec Announces Repricing of Warrants

Nov 14, 2016 06:00 am ET

Fennec Provides Corporate Update and Announces Third Quarter 2016 Results

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the third quarter ended September 30, 2016.

Nov 14, 2016 05:58 am ET

Fennec Provides Corporate Update and Announces Third Quarter 2016 Results

Oct 24, 2016 06:00 am ET

Fennec Announces Update of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the International Society of Paediatric Oncology (SIOP) 2016 Meeting

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced the presentation of updated interim results of SIOPEL 6 at the 2016 SIOP meeting in Dublin, Ireland on October 22, 2016.

Oct 24, 2016 05:58 am ET

Fennec Announces Update of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the International Society of Paediatric Oncology (SIOP) 2016 Meeting

Sep 08, 2016 06:00 am ET

Fennec to Present at Rodman & Renshaw 18th Annual Global Investment Conference in New York on September 13, 2016

Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF) today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The Company will be presenting at 3:25 EDT on Tuesday, September 13, 2016. The conference is being held at the Lotte New York Palace Hotel in New York City.

Sep 08, 2016 05:58 am ET

Fennec to Present at Rodman & Renshaw 18th Annual Global Investment Conference in New York on September 13, 2016

Aug 12, 2016 06:00 am ET

Fennec Provides Corporate Update and Announces Second Quarter 2016 Results

Aug 12, 2016 05:58 am ET

Fennec Provides Corporate Update and Announces Second Quarter 2016 Results

SIOPEL 6 interim results presented in oral presentation at ASCO 2016 confirms no evidence of tumor protection and is consistent with previous updates. Initial hearing efficacy data are "encouraging" with final hearing results expected in H2 2017....

Aug 11, 2016 06:00 am ET

Fennec Announces Appointment of Marco Brughera to the Board of Directors

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today the appointment of Marco Brughera, DVM, CEO and Global Head of Sigma Tau Rare Disease, to its Board of Directors.

Aug 11, 2016 05:58 am ET

Fennec Announces Appointment of Marco Brughera to the Board of Directors

Jul 06, 2016 05:00 am ET

Fennec to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference in New York on July 13, 2016

Fennec Pharmaceuticals, Inc. (TSX: FRX) (OTCQB: FENCF), today announced that the Company will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York City at 10:45 AM EDT on Wednesday, July 13, 2016. The conference is being held at the Le Parker Meridian in New York City.

Jul 06, 2016 04:58 am ET

Fennec to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference in New York on July 13, 2016

Fennec Pharmaceuticals, Inc. (TSX:FRX) (OTCQB:FENCF), today announced that the Company will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York City at 10:45 AM EDT on Wednesday, July 13, 2016. The conference is being held...

Jun 08, 2016 05:00 pm ET

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated May 9, 2016 (the "Circular") for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held in Boston, Massachusetts on June 8, 2016 (the "Meeting"). Detailed results of the vote for the election of directors are set out below:

Jun 08, 2016 04:58 pm ET

Fennec Announces Results of Annual Meeting

Jun 06, 2016 06:00 am ET

Fennec Announces Interim Results of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the American Association of Clinical Oncology (ASCO) 2016 Meeting

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today the results presented at the 2016 ASCO meeting in Chicago, Illinois on June 5, 2016.

Jun 06, 2016 05:58 am ET

Fennec Announces Interim Results of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the American Association of Clinical Oncology (ASCO) 2016 Meeting

May 18, 2016 05:44 pm ET

Fennec Announces Upcoming Events and Presentations

May 18, 2016 05:44 pm ET

Fennec Announces Upcoming Events and Presentations

May 16, 2016 11:49 am ET

Fennec Announces Second Closing of Private Placement

May 16, 2016 11:49 am ET

Fennec Announces Second Closing of Private Placement

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed the second closing of the previously announced non-brokered US$5,000,000 private placement (the "Offering"). On the second closing, Essetifin SpA (formerly Sigma Tau Finanziaria SpA) acquired 1,538,751 common shares for gross proceeds of US$2,923,626.90. Together with

May 12, 2016 06:00 am ET

Fennec Provides Corporate Update and Announces First Quarter 2016 Results

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the first quarter ended March 31, 2016.

May 12, 2016 05:58 am ET

Fennec Provides Corporate Update and Announces First Quarter 2016 Results

Apr 20, 2016 10:11 pm ET

Fennec Announces Sodium Thiosulfate Presentation for Prevention of Ototoxicity in Children at ASCO Meeting

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that interim results from "SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulfate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)" has been accepted for an oral presentation

Apr 20, 2016 10:11 pm ET

Fennec Announces Sodium Thiosulfate Presentation for Prevention of Ototoxicity in Children at ASCO Meeting

Apr 08, 2016 07:59 am ET

Fennec Announces $5.0 Million Private Placement of Common Shares by Sigma Tau Finanziaria

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it intends to complete a non-brokered private placement (the "Offering") of 2,631,579 common shares for gross proceeds of US$5,000,000. The common shares of the Company (the "Shares") will be issued at a price of US$1.90 per Share. The current number of outstanding Shares,

Mar 28, 2016 04:11 pm ET

Fennec Provides Corporate Update and Announces Fiscal Year Ended December 31, 2015 Financial Results

Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2015.

Ad blocking detected

Fennec Pharmaceuticals Inc. (T:FRX)

Business Focus: Bio Therapeutic Drugs